With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and Datroway (datopotamab deruxtecan) in July 2020, except in Japan where ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu has been approved in the European Union as monotherapy for the treatment of adult patients with advanced non-small ...

AstraZeneca said on Monday a mid-stage trial of its cancer drug Enhertu, co-developed with Daiichi Sankyo, showed positive results across multiple HER2-expressing advanced solid tumours in heavily ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo Company, Limited (DSKYF.PK) said that enhertu significantly improved progression-free survival in destiny-breast03 head-to-head phase 3 ...

(Reuters) -AstraZeneca said a late-stage trial had confirmed the benefit of breast cancer drug Enhertu in patients with an advanced form of the disease who had been previously treated with another ...

AstraZeneca and Daiichi Sankyo have officially escalated the competition in HER2-positive breast cancer treatment. Thursday, AZ and Daiichi said the FDA has approved their rising star Enhertu for ...

The AstraZeneca and Daiichi Sankyo targeted cancer drug Enhertu is now the first therapy in its class approved for treating solid tumors regardless of either the cancer type or where the disease ...

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) is the lead product in the ADC Franchise of the Daiichi Sankyo Cancer Enterprise and the most advanced program in AstraZeneca’s ADC scientific platform.